Cheminformatics identification of phenolics as modulators of penicillin binding protein (PBP) 2x of Streptococcus pneumoniae towards interventive antibacterial therapy
Abstract
Infections caused by multidrug-resistant Streptococcus pneumoniae remain the leading cause of pneumonia-related deaths in children < 5 years globally, and mutations in penicillin-binding protein (PBP) 2x have been identified as the major cause of resistance in the organism to beta-lactams. Thus, the development of new modulators with enhanced binding of PBP2x is highly encouraged. In this study, phenolics, due to their reported antibacterial activities, were screened against the active site of PBP2x using structure-based pharmacophore and molecular docking techniques, and the ability of the top-hit phenolics to inhibit the active and allosteric sites of PBP2x was refined through 120 ns molecular dynamic simulation. Except for gallocatechin gallate and lysidicichin, respectively, at the active and allosteric sites of PBP2x, the top-hit phenolics had higher negative binding free energy ({Delta}Gbind) than amoxicillin [active site (-19.23 kcal/mol), allosteric site (-33.75 Kcal/mol)]. Although silicristin had the best broad-spectrum effects at the active (-38.41 kcal/mol) and allosteric (-50.54 kcal/mol) sites of PBP2x, the high thermodynamic entropy (4.90 [A]) of the resulting complex might suggest the need for its possible structural refinement for enhanced potency. Interestingly, silicristin had a predicted synthetic feasibility score of < 5 and quantum calculations using the DFT B3LYP/6-31G+ (dp) revealed that silicristin is less stable and more reactive than amoxicillin. These findings point to the possible benefits of the top-hit phenolics, and most especially silicristin, in the direct and synergistic treatment of infections caused by S. pneumoniae. Accordingly, silicristin is currently the subject of further confirmatory in vitro research.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sublethal β-lactam antibiotics induce PhpP phosphatase expression and StkP kinase phosphorylation in PBP-independent β-lactam antibiotic resistance of Streptococcus pneumoniae
- Restricted sequence variation in Streptococcus pyogenes penicillin binding proteins
A. Hayes, J. A. Lacey, … S. Y. C. Tong·mSpherePeer-reviewed·Apr 29, 2020
- Diversity of penicillin-binding protein 2x in Streptococcus pyogenes from England and Wales, 2001 to 2015
Greta Sveikauskaite, Asha L Marshall, … Valerie W. C. Soo·bioRxiv·Sep 21, 2026
- Pharmacophore modeling, 2D-QSAR, Molecular Docking and ADME studies for the discovery of inhibitors of PBP2a in MRSA
Fredrick Mutie Musila, Grace Wairimu Gitau, … Patrisio Njiru Njeru·Journal of Biomolecular Structure and DynamicsPeer-reviewed·May 19, 2025
- In Silico Identification and In Vitro Validation of Novel KPC-2 β-lactamase Inhibitors
R. Klein, P. Linciano, … D. Tondi·bioRxiv·Aug 20, 2018
- Sorafenib, a clinically approved kinase inhibitor attenuates Streptococcus pneumoniae pathogenesis in vivo by targeting serine/threonine kinase StkP
Joel Abraham, Aswathy C. Sagilkumar, … Karthik Subramanian·mBioPeer-reviewed·Jun 16, 2026